急性肾损伤随访门诊与患者结局及医疗流程的关联:一项队列研究
该倾向匹配队列研究纳入加拿大安大略省一家临床中心2013年2月1日至2017年9月30日因急性肾损伤住院且出院时未接受透析的患者,将164例急性肾损伤随访门诊患者与656例标准治疗患者匹配。中位随访2.2±1.3年,随访门诊与主要不良肾脏事件减少无关(HR 0.91,95%CI 0.75-1.11),但与全因死亡率降低相关(HR 0.71,95%CI 0.55-0.91),且≥66岁患者更可能接受β受体阻滞剂和他汀类药物。
要点
- 急性肾损伤随访门诊与主要不良肾脏事件减少无关(HR 0.91,95%CI 0.75-1.11)。
- 急性肾损伤随访门诊与全因死亡率降低相关(HR 0.71,95%CI 0.55-0.91)。
- ≥66岁随访门诊患者更可能接受β受体阻滞剂(HR 1.34)和他汀类(HR 1.35)。
核心结论
- 急性肾损伤幸存者出院后专科随访与主要不良肾脏事件风险降低无关,但与死亡风险降低及部分心脏保护药物处方增加相关。
研究设计与样本
- 倾向匹配队列研究,纳入加拿大安大略省一家临床中心2013年2月1日至2017年9月30日因急性肾损伤住院且出院时未接受透析的患者。
- 将164例急性肾损伤随访门诊患者与656例标准治疗患者按倾向评分1:4匹配,采用Cox比例风险模型分析,并对对照组随机分配索引日期以避免永恒时间偏倚。
主要发现
- 平均随访2.2±1.3年,随访门诊组与标准治疗组主要不良肾脏事件发生率分别为22.1 vs 24.7例/100患者年(HR 0.91,95%CI 0.75-1.11)。
- 随访门诊与全因死亡率降低相关(HR 0.71,95%CI 0.55-0.91)。
- ≥66岁随访门诊患者更可能接受β受体阻滞剂(HR 1.34,95%CI 1.02-1.77)和他汀类药物(HR 1.35,95%CI 1.05-1.74),但血管紧张素转换酶抑制剂或血管紧张素受体阻滞剂无显著差异(HR 1.21,95%CI 0.94-1.56)。
临床怎么用
- 原文未据此给出推荐。
局限性
- 单中心研究。
- 残余混杂。
以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。
原文
RATIONALE & OBJECTIVE: To determine whether attendance at an acute kidney injury (AKI) follow-up clinic is associated with reduced major adverse kidney events. STUDY DESIGN: Propensity-matched cohort study. SETTING & PARTICIPANTS: Patients hospitalized with AKI in Ontario, Canada, from February 1, 2013, through September 30, 2017, at a single clinical center, who were not receiving dialysis when discharged. EXPOSURE: Standardized assessment by a nephrologist. OUTCOMES: Time to a major adverse kidney event, defined as death, initiation of maintenance dialysis, or incident/progressive chronic kidney disease. ANALYTICAL APPROACH: Propensity scores were used to match each patient who attended an AKI follow-up clinic to 4 patients who received standard care. Cox proportional hazards models were fit to assess the association between the care within an AKI follow-up clinic and outcomes. To avoid immortal time bias, we randomly assigned index dates to the comparator group. RESULTS: We matched 164 patients from the AKI follow-up clinic to 656 patients who received standard care. During a mean follow-up of 2.2±1.3 (SD) years, care in the AKI follow-up clinic was not associated with a reduction in major adverse kidney events relative to standard care (22.1 vs 24.7 events per 100 patient-years; HR, 0.91 [95% CI, 0.75-1.11]). The AKI follow-up clinic was associated with a lower risk of all-cause mortality (HR, 0.71 [95% CI, 0.55-0.91]). Patients aged at least 66 years who attended the AKI follow-up clinic were more likely to receive β-blockers (HR, 1.34 [95% CI, 1.02-1.77]) and statins (HR, 1.35 [95% CI, 1.05-1.74]), but not angiotensin-converting enzyme inhibitors or angiotensin receptor blockers (HR, 1.21 [95% CI, 0.94-1.56]). LIMITATIONS: Single-center study and residual confounding. CONCLUSIONS: Specialized postdischarge follow-up for AKI survivors was not associated with a lower risk of major adverse kidney events but was associated with a lower risk of death and increased prescriptions for some cardioprotective medications.
引用
- Silver SA, Adhikari NK, Jeyakumar N, et al. Association of an Acute Kidney Injury Follow-up Clinic With Patient Outcomes and Care Processes: A Cohort Study. Am J Kidney Dis. 2022. PMID: 36521779. doi:10.1053/j.ajkd.2022.10.011
供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。